AstraZeneca's Advanced Liver Cancer Treatment Data Shows Improved Survival Rates
29 Juni 2023 - 4:02PM
Dow Jones News
By Michael Susin
AstraZeneca said Thursday that phase III studies showed that
Imfinzi plus Imjudo provided a sustained and clinically meaningful
overall survival benefit in patients with advanced liver
cancer.
The pharmaceutical major said that data showed an overall
survival benefit at four years for patients with unresectable
hepatocellular carcinoma who hadn't received prior systemic therapy
and weren't eligible for localized treatment.
The company added that the treatment reduced the risk of death
by 22% compared to other treatments.
"Historically, only 7% of patients with advanced liver cancer
have survived five years, making the [phase III clinical trial]
Himalaya long-term survival data especially meaningful," lead
Investigator in the trial Bruno Sangro said.
Write to Michael Susin at michael.susin@wsj.com
(END) Dow Jones Newswires
June 29, 2023 09:46 ET (13:46 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jul 2023 bis Jul 2024